Society for Risk Aanalysis 2005には「ナノマテリアルとナノテクノロジーの政策形成のためのリスク管理課題のフレーミング:規制アプローチvs.自発的アプローチ」というセッションがあった。
M9.1 An Overview of Regulatory Considerations For FDA Regulated Products Incorporating Nanotechnology. Alderson NA; US Food and Drug Administration
M9.2 Nanotechnology: The Impact of the Proactive Consideration of Ethical, Environmental, Economic, Legal and Social Issues (NE3LS) on Policy Development in Canada . Sheremata L; University of Alberta
M9.3 In Search of a Consistent International Regulatory Approach. Kalpin M, Votaw J*; Wilmer Cutler Pickering Hale and Dorr LLP
M9.5 U.S. Environmental Protection Agency Perspectives on Regulating Nanotechnology. Willis J.; Chemical Control Division Office of Pollution Prevention and Toxics, U.S. EPA
M9.6 Social concerns about Nanotechnology and its Impact for Risk Governance. Renn O.; University of Stuttgart, Germany
M18.1 Nanobiotechnology: Responsible Action on Issues in Society and Ethics (Nanobio-RAISE) . Bennett DJ; European Federation of Biotechnology
M18.2 Regulatory Efforts of the NNCO. Teague EC; National Nanotechnology Coordination Office
M18.3 Regulatory Aspects Of Nanotechnology: What Regulatory Agencies Are Up To And How Agency Actions May Impact Commercial Developments. Bergeson LL; Bergeson & Campbell, P.C.
もうひとつ「リスク解析とナノテクノロジー:現在のパラダイムはどのくらいニーズを満たしているか?」より。
M27.1 U.S. and U.K. Media Coverage of Nanotechnology’s Environmental and Health Risks. Friedman S, Egolf B; Lehigh University
M27.2 Developing a Decision Framework with Underlying Uncertainty: A Case Study in Assessing the Safety of Nano-particles. Morgan Kara; US Food and Drug Administration